Liver Disease Therapeutic Market Report by Therapy Type (Anti-Rejection Drugs/Immunosuppressants, Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulins, Corticosteroids, and Anti-Viral Drugs) Disease Type (Non-alcoholic Fatty Liver Disease (NAFLD), Viral Hepatitis (B, C, D), Alcoholic Liver Disease (ALD), and Autoimmune Liver Disease (ALD)) End Users (Hospitals, Laboratories, and Others) Regions and Company Analysis 2024-2032

Liver Disease Therapeutic Market Analysis

The Global Liver Disease Therapeutic Market is on a steady upward trajectory. It is projected to reach US$ 28.98 billion by 2032, up from US$ 13.86 billion in 2023. This robust growth, with a CAGR of 8.54% from 2024 to 2032, is a testament to the increasing demand and potential in the field of liver disease treatment.

The liver, a vital organ for overall health, can be affected by various diseases. However, there is hope on the horizon. Genetic strategies with high liver tropism, such as gene addition/editing and silencing, are being developed to combat these diseases. While the gene addition and editing technique has shown promise in clinical trials, challenges remain regarding immune response and long-term stability. Similarly, mRNA therapy, a cutting-edge approach, has demonstrated potential in treating liver-related disorders. Using siRNAs and antisense oligonucleotides for gene silencing, specifically targeting hepatocytes, has paved the way for siRNA-based treatments for liver disorders. Enzyme substitution therapy also holds promise for mutations resulting in loss of function.

The increasing incidence of Cancer, hepatitis, autoimmune diseases, and nonalcoholic fatty liver diseases is driving the growth of liver disease treatment. The growing old population significantly contributes to the increasing number of liver disease patients, given that their immunity starts waning with age. Additionally, the rise in government healthcare expenditures to make treatments affordable and accessible for the citizenry will also aid in the growth of the liver disease treatment industry. A research study published in the Clinical Liver Disease journal in June 2021 highlighted that chronic liver disease (CLD) affects about 1.5 billion people globally and is a leading cause of death and illness worldwide. The most common causes of prevalent liver disease, according to the American Association for the Study of Liver Disease's publication in June 2021, are nonalcoholic fatty liver disease (NAFLD) at 59%, followed by hepatitis B at 29%, hepatitis C at 9%, and alcoholic liver disease at 2%.

According to a study published in Clinical and Molecular Hematology, the global prevalence of nonalcoholic fatty liver disease (NAFLD) is forecasted to reach 55.7% by 2040, driving growth in the overall market for liver disease treatments.

The growing prevalence of liver diseases and the crucial role of government and non-profit organizations in raising awareness worldwide. It specifically mentions the efforts of organizations such as the International Liver Transplantation Society (ILTS), the International Living Donor Liver Transplantation Study Group (iLDLT), and the Liver Transplant Society of India (LTSI) in promoting awareness of liver-related diseases and supporting research and development to prevent, treat, and cure liver diseases. These organizations recently held Asia's first consensus conference on caring for patients who receive small liver grafts in India. 

So, the main things that are driving the growth of the market during the upcoming years are:

• The rise in liver diseases around the world.
• There is a rise in the number of people who drink too much and eat poorly.
• There is a rise in government efforts to raise awareness about liver diseases.

North America Liver Disease Therapeutics Market

North America is the largest market for clinical trial studies, primarily due to the presence of research and academic institutions. Additionally, changes in lifestyle, such as increased alcohol consumption and unhealthy eating habits, have led to a higher prevalence of liver disease. Over the next few years, the regional market is projected to expand due to heightened patient awareness regarding their health and the development of new products to address unmet medical needs.

The incidence of liver diseases has increased in the United States, with 4.5 million adults diagnosed as of January 2023. High alcohol consumption is a significant factor contributing to this increase, with about 25.1% of adults engaging in heavy drinking. As a result, the burden of liver diseases in the country is expected to rise, which is anticipated to have a positive impact on the market. The management of liver diseases has evolved rapidly due to the rising prevalence of liver diseases. Companies focus on research and development to address unmet needs for preventing liver disease progression and reducing anticipated mortality. Altimmune, Inc. announced positive results from its trial of Pemvidutide for non-alcoholic fatty liver disease, showing potential to lower liver fat content and inflammation. Madrigal Pharmaceuticals, Inc. also announced positive clinical data from its phase 3 study of Resmetirom for Non-Alcoholic Fatty Liver Disease.

Liver Disease Therapeutics Market

The major players are Abbott Laboratories, Astellas Pharma Inc, Bristol-Mayers Squibb, Gilead Sciences, GlaxoSmithKline Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Sanofi S.A, Pfizer Inc. and Takeda Pharmaceuticals.

Therapy Type

1.    Anti-Rejection Drugs/Immunosuppressants
2.    Chemotherapy Drugs
3.    Targeted therapy
4.    Vaccines
5.    Immunoglobulins
6.    Corticosteroids
7.    Anti-Viral Drugs

Disease Type

1.    Non-alcoholic Fatty Liver Disease (NAFLD)
2.    Viral Hepatitis (B, C, D)
3.    Alcoholic Liver Disease (ALD)
4.    Autoimmune Liver Disease (ALD)

End Users

1.    Hospitals
2.    Laboratories
3.    Others

Countries – Market has been covered from five Region viewpoints:

1.    North America

1.1    United States
1.2    Canada

2    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

Company Analysis

1.    Abbott Laboratories
2.    Astellas Pharma Inc.
3.    Bristol-Mayers Squibb
4.    Gilead Sciences
5.    GlaxoSmithKline Pharmaceuticals Ltd
6.    F. Hoffmann-La Roche Ltd
7.    Merck & Co. Inc
8.    Novartis AG
9.    Sanofi S.A
10.    Pfizer Inc.
11.    Takeda Pharmaceuticals

Report Details: